PVLA · Palvella Therapeutics, Inc.
$124.15
-33.09 (-21.04%)
At close · Jul 20
Market Cap
$1.78B
Shares
14.34M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$42.81M
+65.3%
FY2023
Net Income
-$41.72M
-139.3%
FY2025
Operating Margin
-27.72%
+140.1pp
FY2023
Diluted EPS
-$3.71
+52.6%
FY2025
Operating Cash Flow
-$25.01M
-130.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.35M | — | — | $42.81M | $25.9M | $31.42M | $29.32M | $46.28M | $29.1M | $25.28M | $5.83M | $2.93M | $5.37M | $12.43M | |
| $2.91M | $2.59M | $642K | — | — | — | — | — | — | — | — | — | — | — | |
| $28.1M | $22.84M | $8.15M | $8.79M | $52.98M | $66.66M | $46.53M | $55M | $41.49M | $22.29M | $19.7M | $8.24M | $5.6M | $9.41M | |
| $17.49M | $15.76M | $5.94M | $3.08M | $16.39M | $16.59M | $16.71M | $18.44M | $18.44M | $17.58M | $8.89M | $8.37M | $6.96M | $2.46M | |
| — | — | — | $1.9M | $2.77M | $2.46M | — | — | — | — | — | — | — | — | |
| $45.59M | $38.6M | $14.1M | $11.87M | $69.38M | $83.25M | $63.24M | $73.44M | $59.93M | $39.87M | $28.59M | $16.61M | $12.56M | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | $12.56M | $11.87M | |
| -$45.59M | -$38.6M | -$14.1M | -$11.87M | -$43.47M | -$51.83M | -$33.92M | -$27.16M | -$30.83M | -$14.59M | -$22.76M | -$13.68M | -$7.2M | $553.83K | |
| — | — | — | -27.72% | -167.84% | -164.97% | -115.68% | -58.68% | -105.94% | -57.74% | -390.31% | -466.62% | -134.17% | 4.46% | |
| — | — | — | -$9.97M | -$40.7M | -$49.37M | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | $2.65M | $493.94K | |
| $471K | $727K | -$131K | $712K | $1.3M | $2.4M | -$3.66M | -$26K | $1.8M | -$2.1M | $120K | $10.91K | -$2.65M | -$487.63K | |
| -$49.3M | -$41.72M | -$17.43M | $18.69M | -$33.28M | -$45.74M | -$37.07M | -$25.47M | -$27.07M | -$16.54M | -$22.64M | -$13.85M | -$9.85M | $66.2K | |
| $0 | $0 | $0 | $0 | $0 | $0 | $164K | $0 | -$312K | $1.1M | $162K | $203.87K | -$18 | — | |
| -$49.3M | -$41.72M | -$17.43M | $18.69M | -$33.28M | -$45.74M | -$37.23M | -$25.47M | -$26.75M | -$17.65M | -$22.8M | -$14.06M | -$9.85M | $66.2K | |
| — | — | — | 43.66% | -128.47% | -145.58% | -126.97% | -55.03% | -91.93% | -69.82% | -391% | -479.5% | -183.59% | 0.53% | |
| -$32.37M | — | -$17.43M | $17.92M | — | — | -$37.23M | -$28.3M | -$26.75M | — | — | — | — | — | |
| -$49.2M | -$41.64M | -$17.43M | $17.92M | -$34.36M | -$44.61M | -$35.53M | -$24.48M | -$25.04M | -$20.84M | -$23.03M | -$14.49M | -$9.74M | $89.31K | |
| USD/shares | — | -$3.71 | -$7.83 | $2.19 | -$36.00 | -$56.80 | -$54.40 | — | — | — | — | — | — | — |
| USD/shares | — | -$3.71 | -$7.83 | $2.17 | — | -$56.80 | -$54.40 | — | — | — | — | — | — | — |
| shares | — | 11.25M | 2.23M | 1.77M | 927.15K | 806.84K | 681.01K | 632.81K | 663.51K | 549.14K | 521.41K | 429.91K | 173.4K | 147.86K |
| shares | — | 11.25M | 2.23M | 1.79M | — | 806.84K | 681.01K | 632.81K | 663.51K | 549.14K | 521.41K | 429.91K | 173.4K | 147.86K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.46×
EV/EBIT
—
Biotechnology median 26.45×
P/E (TTM)
—
Biotechnology median 7.03×
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2019 |
|---|---|
| Customer Revenue | $32,065,000 |
| Collaboration Revenue | $14,214,000 |